Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[203Pb]VMT-α-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors
NCT05111509Phase 1Active, not recruiting
- Start
- Aug 2022
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [203Pb]VMT-alpha-NET in Neuroendocrine Neoplasm (NEN). Primary endpoint: Ability of [203Pb]VMT-α-NET to identify neuroendocrine tumor lesions at 5 days. Started Aug 2022; status: active, not recruiting.
02
Drugs
[203Pb]VMT-alpha-NET
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05111509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111509.